Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816905 | 1.00 | HTT (0.61) | HTTLMNAKMT2AALDH1A1TAS1R3 | |
| SCHEMBL3819848 | 0.94 | HTT (0.51) | HTTLMNAKMT2AALDH1A1TAS1R3 | |
| SCHEMBL14082169 | 0.84 | HTT (0.71) | HTTLMNAKMT2AALDH1A1TAS1R3 | |
| SCHEMBL4919682 | 0.82 | TAS1R3 (0.60) | HTTLMNAKMT2AALDH1A1TAS1R3 | |
| SCHEMBL4928246 | 0.82 | TAS1R3 (0.60) | HTTLMNAKMT2AALDH1A1TAS1R3 | |
| SCHEMBL14082298 | 0.82 | LMNA (0.68) | HTTLMNAKMT2AALDH1A1TAS1R3 | |
| SCHEMBL14009837 | 0.81 | PDE4A (0.52) | HTTLMNAKMT2AALDH1A1TAS1R3 | |
| SCHEMBL3112685 | 0.80 | HTT (0.72) | HTTLMNAKMT2AALDH1A1TAS1R3 | |
| SCHEMBL22289415 | 0.80 | HTT (0.84) | HTTLMNAKMT2AALDH1A1TAS1R3 | |
| SCHEMBL10527008 | 0.80 | HTT (0.80) | HTTLMNAKMT2AALDH1A1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713775-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | EP | claimed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | claimed |
| EP-1713775-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005074643-A2 | BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | claimed |
| EP-1713775-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| EP-1713775-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005074643-A2 | BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275062-A1 | Chemical Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | HTT 1243/4885LMNA 1818/4885KMT2A 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.